Author's response to reviews

Title: Shifting from glucose diagnosis to the new HbA1c diagnosis would reduce the ability of the Finnish Diabetes Risk Score -FINDRISC- in screening glucose abnormalities within a real-life primary healthcare preventive strategy.

Authors:

Bernardo Costa (costaber@gmail.com)
Francisco Barrio (ciscobarrio@gmail.com)
Josep L Piñol (jlpinyol.tarte.ics@gencat.cat)
Juan J Cabre (jcabre.tarte.ics@gencat.cat)
Xavier Mundet (xmundet.bcn.ics@gencat.cat)
Jordi Salas (jordi.salas@urv.cat)
Oriol Solà-Morales (osola@hittinnova.com)
Research Group DE-PLAN-CAT/PREDICE (juanjocabre@gmail.com)

Version: 3 Date: 16 December 2012

Author's response to reviews: see over
16 December 2012

Ursula D'Souza, PhD.
Senior Editor, BMC Medicine
Ref: MS: 4623610108006929

Current title
Shifting from glucose diagnosis to the new HbA1c diagnosis would reduce the ability of the Finnish Diabetes Risk Score – FINDRISC – in screening glucose abnormalities within a real-life primary healthcare preventive strategy.

Dear Dr. D’Souza

Many thanks for the consideration of the second version of this article on behalf of BMC-Medicine. First, we would like to confirm our profound satisfaction with the coincidence of both reviewers to approve our first review of the submitted manuscript. We know that sometimes it is not easy to achieve this level of agreement.

We have revised again the manuscript according to your five specific comments and we enclose the amendments giving a point-by-point response to the concerns.

(1) Please provide email addresses of all authors in the title page according to the instructions…

Current email addresses of all authors have been provided in the title page which has been organized following the publication standards. Please note that we have added a new author ranking sixth in the line of authors of this article. As director of the research group and first responsible for this paper I certify that Dr. R. Sagarra (RS) meets all the criteria required by BMC-Medicine for inclusion. Their contribution has also been specified in the “Authors’ contributions” paragraph in order to give the appropriate credit.

(2) Structure the abstract to include background rather than aim.

The structure of the abstract has been adapted to the recommendation after changing the title of the corresponding section.

(3) Please place keywords and abbreviations in the correct part of the manuscript according to the guidelines…

Both paragraphs have been rearranged according to your comments following the guidelines of publication.

(4) Place competing interests, author contributions and acknowledgement sections in correct part of the manuscript…

We proceed similarly to the previous comment. In fact, we have tried to make this new version of the manuscript to fit the journal style at all levels.
(5) Ensure the manuscript adheres to STROBE guidelines for cross-sectional studies…

We agree with the conceptual comment raised by the editor: the first phase of the DE-PLAN-CAT study is not a clinical trial. Therefore, a trial registration number is not required and all reference has been removed.

At this advanced stage we hope that this third version is found suitable for publication. If so, we would very much appreciate the letter of acceptance for academic purposes. Of course, we continue always at your disposal if you require further corrections.

We look forward to hearing from you as soon as possible.

Sincerely yours

Dr. Bernardo Costa
Diabetes and Metabolism Research Area
Jordi Gol Primary Health Care Research Institute
Catalan Health Institute